The report ‘ Protein Expression ‘ Market is segmented by By System Type (Prokaryotic Expression Systems (Vagus Nerve Stimulation, Escherichia coli Systems and Other Systems), Insect Cell Expression Systems (CHO Systems and Other Systems), Yeast Cell Expression Systems (Kluyveromyces Lactis Systems, Saccharomyces Systems, Pichia Systems and Other Systems), Cell-free Expression Systems and Algal-based Expression Systems), By Product (Reagents, Competent cells, Expression vectors, Services and Instruments), By Application (Therapeutic Applications, Industrial Applications and Research Applications), By End-User (Pharmaceutical and biotechnological companies, Academic research Institutes, Contract research organizations and Others) – Global Forecast to 2030. In 2020, the valuation of the protein expression market was $2.31 billion. It is predicted to reach $8.1 billion by 2030, representing a CAGR of 13.31 percent throughout the period of 2020-2030.
Key factors augmenting the growth of the market
Due to the increasing demand for the biopharmaceutical industry as well as biologics, the overall demand for Protein Expression Market is growing rapidly. Also, it is expected to do so in the next upcoming years. In the year 2020, CDER had successfully approved around 53 novel drugs, either as NMEs (new molecular entities) under NDAs (New Drug Applications) or as new therapeutic biologics under Biologics License Applications (BLAs).
Moreover, biotechnology, Biopharma firms are widely concentrating in terms of producing new and advanced methods to treat and cure a vast range of acute and chronic diseases and medical conditions. The National Health Council stated that chronic diseases affect around 133 Mn Americans, which represents more than 40 percent of the entire population of the country.
By System Type, the Prokaryotic expression systems segment held the largest share of the Protein Expression Market in 2020.
Based on system type, the entire Protein Expression Market has been classified into Prokaryotic Expression Systems, Insect Cell Expression Systems, Yeast Cell Expression Systems, Cell-free Expression Systems and Algal-based Expression Systems. The Prokaryotic expression systems held the largest proportion of the market share owing to their wide range of applications in terms of producing drugs and in biologics as well. On the other hand, the segment ‘Mammalian cell expression systems’ showed the fastest growth rate in the year 2020 and are expected to continue throughout the forecasted period. It is primarily due to factors like the increasing demand for the manufacturing of biologics and for proteomics research.
By Product, the Reagents possessed the largest segment of the Protein Expression Market in 2020.
Based on product, the entire Protein Expression Market has been segmented into Reagents, Competent cells, Expression vectors, Services and Instruments. Among these segments, the reagents segment contained the largest share of the market, and the factors that are responsible for this are due to its repetitive purchase in the domains like therapeutic, industrial, and research applications. On the other hand, the segment ‘services’ is anticipated to expand at the highest CAGR rate due to the growing trend of outsourcing protein expression services by the manufacturers of the drug as well as the research labs.
By Application, the Therapeutic application dominated the entire Protein Expression Market in 2020.
In terms of Applications, the entire Protein Expression Market has been segregated into Therapeutic Applications, Industrial Applications and Research Applications. Among all these market segments, the Therapeutic application market segment held the largest market share of about more than 50 percent of the total Protein Expression Market share in 2020, which can primarily be attributed to the high demand for therapeutic proteins for the cure of infectious diseases, haemophilia, cancer, anaemia, and multiple sclerosis.
In terms of end-user, the pharmaceutical and biotechnological companies dominated the entire Protein Expression Market in 2020.
Based on end-user, the entire Protein Expression Market has been divided into Pharmaceutical and biotechnological companies, Academic research Institutes, Contract research organizations and Others. Among all these segments, the pharmaceutical and biotechnological companies segment possessed the highest market share in terms of revenue in the year 2020. It is mainly due to the increasing focus on proteomics research and the rising manufacturing of biologics products.
Based on the regional segment, North America had the maximum Protein Expression Market share in 2020.
On a regional basis, the entire Protein Expression Market has been segmented into North America, Europe, APAC and LAMEA. Among all these regions, North America comprehensively dominated the market in 2020 and also it is expected to show its sheer dominance all over the forecasted period. It is mainly because of the availability of a vast number of biotechnology and biopharmaceutical companies in this region. On the other hand, the Asia Pacific region is estimated to expand at the highest CAGR rate during the anticipated time period. It is due to the presence of hidden growth opportunities in developing as well as emerging countries, including India and China.
Significant market players operating in the market
Some of the key leading players that are operating in this entire market are GenScript Biotech Corporation, Lucigen Corporation, Oxford Expression Technologies Ltd., LifeSensors, ProMab Biotechnologies Inc., ARTES Biotechnology GmbH, Bioneer Corporation, Synthetic Genomics Inc., Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Takara Bio, Inc., Bio-Rad Laboratories Inc., Jena Bioscience GmbH, Lonza, Promega Corporation, New England Biolabs, ProteoGenix, Peak Proteins Ltd., Sino Biological Inc.,etc.
- On November 15, 2021, FlashBAC announced that it is planning to produce Proteins For Zika Antibody and Dengue Tests. Oxford Expression Technology’s flashBAC expression system was selected as a key tool to produce the glycoproteins for the improvisation of a novel antigen lateral flow antibody test for the detection of Zika and dengue.
- On October 13th, 2021, Cellumed Co. Ltd., and a German-based company, ARTES Biotechnology GmbH, together declared the execution of a Development and License Agreement with the aim of generating microbial production of cell lines, documentation and processes associated with the cGMP manufacturing of enzymes that is necessary for the entire manufacturing process of mRNA vaccines.
On June 18th 2020, Lonza announced the introduction of its New GSv9 Media to maximize the performance of its GS Gene Expression System for the optimization of recombinant protein production. The GSv9 Media’s operating parameters are quite simple to apply, thus resulting in the maximization of its product yields & developing the consistency to meet the variety of scalability requirements of the key biopharmaceutical manufacturers existing in the market.